Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

被引：0
|
作者：
Shigehisa Kitano
Toshio Shimizu
Takafumi Koyama
Takahiro Ebata
Satoru Iwasa
Shunsuke Kondo
Akihiko Shimomura
Yutaka Fujiwara
Noboru Yamamoto
Anne Paccaly
Siyu Li
Petra Rietschel
Tasha Sims
机构：
[1] National Cancer Center Hospital,Department of Experimental Therapeutics Koto
[2] Regeneron Pharmaceuticals,ku
[3] Inc.,undefined
[4] Regeneron Pharmaceuticals,undefined
[5] Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
Cemiplimab; Anti–PD-1; Immunotherapy; Advanced tumors; Japanese patients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：53 / 64
页数：11
相关论文
共 50 条
  • [41] A PHASE 1 STUDY OF NECITUMUMAB (ANTI-EGFR MONOCLONAL ANTIBODY) IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Tamura, Yosuke
    Tanabe, Yuko
    Honda, Kazunori
    Asahina, Hajime
    Enatu, Sotaro
    Kurek, Raffael
    Yamada, Yasuhide
    Tamura, Tomohide
    ANNALS OF ONCOLOGY, 2014, 25
  • [42] A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.
    Kotasek, Dusan
    Coward, Jermaine
    de Souza, Paul L.
    Underhill, Craig
    Jin, Xiaoping
    Li, Baiyong
    Xia, Yu
    Prawira, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.
    Sanborn, Rachel E.
    Bordoni, Rodolfo Eduardo
    Fleming, Gini F.
    Khasraw, Mustafa
    Hawthorne, Thomas
    Thomas, Lawrence J.
    Rawls, Tracey
    Young, Diane C.
    Golden, Philip
    Keler, Tibor
    Yellin, Michael Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
    Zucali, Paolo Andrea
    Lin, Chia-Chi
    Carthon, Bradley C.
    Bauer, Todd M.
    Tucci, Marcello
    Italiano, Antoine
    Iacovelli, Roberto
    Su, Wu-Chou
    Massard, Christophe
    Saleh, Mansoor
    Daniele, Gennaro
    Greystoke, Alastair
    Gutierrez, Martin
    Pant, Shubham
    Shen, Ying-Chun
    Perrino, Matteo
    Meng, Robin
    Abbadessa, Giovanni
    Lee, Helen
    Dong, Yingwen
    Chiron, Marielle
    Wang, Rui
    Loumagne, Laure
    Lepine, Lucie
    de Bono, Johann
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [45] Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors.
    Song, Xuyang
    Pak, Min
    Chavez, Carlos
    Liang, Meina
    Lu, Hong
    Schwickart, Martin
    Blake-Haskins, John A.
    Robbins, Paul B.
    Jin, Xiaoping
    Gupta, Ashok Kumar
    Roskos, Lorin
    Narwal, Rajesh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study.
    Lin, Chia-Chi
    Zucali, Paolo
    Carthon, Bradley
    Bauer, Todd M.
    Tucci, Marcello
    Italiano, Antoine
    Iacovelli, Roberto
    Su, Wu-Chou
    Massard, Christophe
    Saleh, Monsoor
    Daniele, Gennaro
    Greystoke, Alastair
    Gutierrez, Martin
    Pant, Shubham
    Shen, Ying-Chun
    Perrino, Matteo
    Meng, Robin
    Abbadessa, Giovanni
    Lee, Helen
    Dong, Yingwen
    Chiron, Marielle
    Wang, Rui
    Loumagne, Laure
    de Bono, Johann
    de Bono, Johann
    CANCER RESEARCH, 2021, 81 (13)
  • [47] A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL DOSE-ESCALATION RESULTS
    Johnson, Melissa
    Lakhani, Nehal
    Girda, Eugenia
    Olszanski, Anthony
    Fong, Lawrence
    Han, Hyunsil
    Casey, Kerry
    Li, Siyu
    Visich, Jennifer
    Skokos, Dmitris
    Seebach, Frank
    Lowy, Israel
    Fury, Matthew
    Mathias, Melissa
    Segal, Neil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A767 - A768
  • [48] Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
    Gambale, Elisabetta
    Fancelli, Sara
    Caliman, Enrico
    Petrella, Maria Cristina
    Doni, Laura
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [49] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] A phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas
    Shen, L.
    Li, J.
    Xu, N.
    Xing, B.
    Zhang, Q.
    Zhao, Y.
    Cao, J.
    Ding, J.
    Wang, J.
    Wang, Y.
    Dai, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 516 - 516
12345